Hypnite

Indicated to address sleep latency and maintenance by modulating neurotransmitter activity in the central nervous system.

Strengths: 1 · 2 · 3mg

Medicine details

Conditions
Alternative names

Lunesta

Therapeutic class

Cyclopyrrolone Hypnotic

Pharmacological class

Nonbenzodiazepine Hypnotic

Contraindications

hypersensitivity to eszopiclone; myasthenia gravis

Minor side effects

unpleasant taste; headache; somnolence; dizziness

Moderate side effects

diarrhoea; nausea; xerostomia; peripheral oedema

Dosage forms

Film-coated tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

Hab Pharma

Onset Time

30–60 minutes

Duration

6–8 hours

Storage instructions

Store in a cool, dry place away from moisture.

Drug interactions

alcohol; benzodiazepines; opioids; anticonvulsants

Age restrictions

Adults only.

Serious side effects

anaphylaxis — requires immediate medical attention; hallucinations — requires immediate medical attention

Patient summary

Indicated to address sleep latency and maintenance by modulating neurotransmitter activity in the central nervous system.

Mechanism of action

Eszopiclone interacts with the GABA-A receptor complex, enhancing neuronal inhibition and effectively reducing the time required to fall asleep while helping to maintain sleep continuity.

Pregnancy and breastfeeding

Pregnancy: Use only if potential benefit outweighs risk. Breastfeeding: Not recommended.

Hypnite

Indicated to address sleep latency and maintenance by modulating neurotransmitter activity in the central nervous system.

Editorial Notes

  • Active ingredient(s): Eszopiclone
  • Listed indication(s): Insomnia